CHARLOTTESVILLE, Va., Nov. 5, 2013 /PRNewswire/ -- Donnatal®, one of the medical world's most often-prescribed medications used to treat Irritable Bowel Syndrome (IBS), received an important revalidation in a recently-released study presented at the Annual Scientific Meeting of the American College of Gastroenterology (ACG) in San Diego, California.
A poster presentation by Dr. Ralph R. Turner of Phase V Technologies released the results of an analysis of a previous clinical trial on the drug Donnatal® (Phenobarbital and Belladonna Alkaloids) that compared Donnatal® to phenobarbital alone, Belladonna Alkaloids alone and a placebo for treatment of IBS. The study, produced from original Donnatal® clinical trial data by Phase V Technologies, received a presidential poster award and showed that Donnatal® was more effective than other treatments (phenobarbital alone, belladonna alone and placebo) in alleviating night pain among female patients with Irritable Bowel Syndrome (IBS). Additionally, patients with IBS-C (constipation) significantly increased Bowel Movement (BM) frequency while patients with IBS-D (diarrhea) reported significant decreased BM frequency.
The study, said Kevin W. Combs, Executive Vice President of PBM Pharmaceuticals, employed contemporary statistical methods to analyze earlier data, and demonstrates the value of Donnatal® to positively impact the symptoms of IBS. "It's important for patients with unmet medical needs to have treatment options," said Combs, "and it is particularly noteworthy when we are talking about a product like Donnatal®, which has such a long history of providing relief to so many dealing with IBS. These outcomes support thousands of physicians who have been prescribing Donnatol® for more than 40 years to help patients with their IBS symptoms."
For more information on this study and Donnatol®, please contact Mike Etchemendy at PBM Pharmaceuticals, Inc. at 434-980-8100 or visit www.donnatal.com.
PBM Pharmaceuticals, located in Charlottesville, VA, is a rapidly growing, specialty pharmaceutical company that specializes in selling, distributing, marketing, manufacturing and reviving Rx products that help improve patients' health and quality of life. PBM utilizes the latest in technology and an entrepreneurial spirit to maximize physician coverage and capture growth opportunities. PBM has a web-based platform, superior data segmentation insights, dynamic collateral programs and strong scalable infrastructure and support systems designed to enable maximum growth. For more information, please visit www.pbmpharmaceuticals.com
Phase V Technologies, located in Wellesley Hills, MA, was established in 1987 as an independent organization of medical and health technology research specialists with advanced training in medicine, clinical research, biostatistics, epidemiology, health economics and psychology. The company was originally founded as a venture of the University of Connecticut Research and Development Corporation to develop new computer-based information systems and technologies for the evaluation, assessment and analytical analyses of patient-reported health outcomes. For more information, please visit www.phasevtechnologies.com
SOURCE PBM Pharmaceuticals